Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
In a wide-ranging interview, WellPoint Inc. CEO Joseph Swedish says adapting to technology is a top priority as he leads the nation's second largest health insurer.
Global firm Covidien LP plans to consolidate U.S. operations for servicing its medical devices in central Indiana, renovating its existing 70,000-square-foot facility in the process.
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
Strand Diagnostics LLC’s Know Error test uses DNA analysis to make sure a tissue sample that has been declared cancerous does, indeed, belong to the patient doctors think it does. But Strand is having trouble convincing Medicare that the test is medically necessary.
Indiana University Health wants to merge two of its big downtown hospitals—University and Methodist—into one location, meaning either one or both would close or be converted to another use.
Fishers will forgive as much as $300,000 in development fees to get a $17.6 million expansion project started by Aug. 1.
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
A bill proposed by four Senate Republicans would give veterans more flexibility to see a private doctor if they are forced to wait too long for an appointment at a Veterans Affairs hospital or clinic.
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
The 5-year-old firm has pledged to invest $20 million to double the size of its corporate headquarters in Indianapolis and lease real estate for a series of 3,500-square-foot health clinics across the state.
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
